XERIS BIOPHARMA HOLDINGS, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $25.69 million as of 2022-12-31, per its 10-K filed 2023-03-08.
Discontinued › Notes
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2023-03-08
- 2022-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $25.69M.
- 2022-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $30.10M.
- 2022-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $30.22M.
- 2022-03-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $25.35M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2022-12-31 | $25.69M 10-K · filed 2023-03-08 |
| 2022-09-30 | $30.10M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $30.22M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $25.35M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $22.53M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |